Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal
September 01, 2020 15:55 ET
|
Intrommune Therapeutics
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
Asthma and Allergy Foundation of America (AAFA) Appoints Melanie Carver Chief Mission Officer
August 06, 2020 08:53 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the...
Survey Confirms Physician Interest in Peanut Allergy Immunotherapy
February 03, 2020 09:04 ET
|
Intrommune Therapeutics
New York, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and other...
Intrommune Participates in 2019 Food Allergy Fund Summit
November 26, 2019 15:41 ET
|
Intrommune Therapeutics
New York, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment for peanut and other food allergies delivered...
POISED Study Supports Risk of Cessation of Oral Immunotherapy for Peanut Allergy; PACE Study Indicates Safer Peanut Allergy Treatment Approaches are Needed
November 07, 2019 10:00 ET
|
Intrommune Therapeutics
New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the...
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
September 16, 2019 14:25 ET
|
Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Therapeutics Receives Support from Allergy & Asthma Network
September 13, 2019 09:05 ET
|
Intrommune Therapeutics
New York, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing the patient-friendly oral mucosal immunotherapy (OMIT) toothpaste platform for...
Newly Published Findings Validate Intrommune’s Approach to Treating Peanut and Other Food Allergies
September 05, 2019 15:20 ET
|
Intrommune Therapeutics
New York, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Therapeutics Receives Formulation Patent Notice of Allowance
August 21, 2019 14:41 ET
|
Intrommune Therapeutics
New York, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Health Fair 11 at the Fair Offers Healthy Options to State Fair Goers
August 15, 2019 17:35 ET
|
Minnesota Health Fairs Inc.
GOLDEN VALLEY, Minn., Aug. 15, 2019 (GLOBE NEWSWIRE) -- The Minnesota State Fair is all about tradition. Fairgoers have their must-eat food(s!), their tried-and-true route around the fairgrounds,...